REG - CRISM Therapeutics - Director Dealing

CRISM' TherapeuticsAnnouncement

07/04/2025 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250407:nRSG9432Da&default-theme=true

RNS Number : 9432D  CRISM Therapeutics Corporation  07 April 2025

7 April 2025

 

CRISM Therapeutics Corporation

(AIM:CRTX)

 

Director Dealing

 

CRISM Therapeutics Corporation ("CRISM" or the "Company") announces that it
has been notified that Non-Executive Director, Gerald Beaney has purchased
20,182 ordinary shares of the Company at a price of 9.88 pence per share.

 

Following this purchase, Mr Beaney holds 45,182 ordinary shares, which
represents approximately 0.14% of the Company's total issued share capital of
32,678,312.

 

 

Enquiries:

 

 Company                         Nomad and Broker                  Financial PR
 CRISM Therapeutics Corporation  S.P. Angel Corporate Finance LLP  Buchanan
 Andrew Webb, CEO                Richard Morrison

 Chris McConville, CSO           Adam Cowl                         Mark Court mark.court@buchanancomms.co.uk

                                                                   Jamie Hooper jamie.hooper@buchanancomms.co.uk
 via Buchanan                    +44 (0) 20 3470 0470              +44 (0) 20 7466 5000

 

 

 

Dealings by Persons Discharging Managerial Responsibilities

 

  1   Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Gerald Beaney

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Director

 b)   Initial notification /Amendment                               Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                          CRISM Therapeutics Corporation

 b)   LEI                                                          213800XFW6MKVCHHPW88

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary shares with no par value

      Identification code                                          ISIN: VGG042401262

 b)   Nature of the transaction                                    Purchase of shares

 c)   Price(s) and volume(s)

Director/PDMR  Price  Volume

                                                                                     Gerald Beaney  9.88   20,182

 d)   Aggregated information

      - Aggregated volume                                           20,182

      - Price                                                      £1,993.98

 e)   Date of the transaction                                      7 April 2025

 f)   Place of the transaction                                     Outside a trading venue

 

 

 

 

 

 

 

 

 

 

 

d)

 

Aggregated information

- Aggregated volume

 20,182

- Price

£1,993.98

e)

 

Date of the transaction

7 April 2025

f)

 

Place of the transaction

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFVISRIDIIE